Reference : Triom une: la tritherapie du pauvre ?
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/40296
Triom une: la tritherapie du pauvre ?
French
[en] A fixed dose anti-HIV combination for the poor? Triomune
Garcia, M Villar [> > > >]
Mukeba-Tshialala, D. [> > > >]
Vaira, Dolorès mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén. >]
2009
Revue Médicale de Liège
Hopital de Baviere
64
1
32-6
Yes (verified by ORBi)
0370-629X
Liège
Belgique
[en] Africa ; Anti-HIV Agents/adverse effects/economics/therapeutic use ; Developing Countries ; Drug Administration Schedule ; Drug Combinations ; HIV Infections/drug therapy/economics ; Humans ; Lamivudine/adverse effects/economics/therapeutic use ; Nevirapine/adverse effects/economics/therapeutic use ; Stavudine/adverse effects/economics/therapeutic use
[en] Despite a relative global stabilization of its incidence, HIV infection remains a major threat for public health, principally in Africa where it concerns more than 22 million people and constitutes the first cause of death on the continent. To face the emergency of the HIV/AIDS epidemics on the African continent, the primary goal is to make available to all patients free and efficient antiretroviral medications. Such a goal cannot be dissociated from large scale prevention campaigns. In 2000, Triomune, one of the first fixed dose combinations of three antiretrovirals (stavudine, lamivudine & nevirapine) was launched by the Indian drug company Cipla, specialized in the production of low cost medications. Its convenient pill burden (one pill twice a day) and its very low cost (around 30 US $ per month) make Triomune an appealing solution for the treatment of HIV/AIDS in Africa. Unfortunately, Triomune presents several drawbacks (low genetic barrier, frequent side effects) and one of its constituents is not used in Europe anymore. Other first line treatments are urgently needed.
http://hdl.handle.net/2268/40296

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Garcia Triomune 2009.pdfPublisher postprint683.04 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.